Date published: 2025-10-2

1-800-457-3801

SCBT Portrait Logo
Seach Input

SRPIN 340 (CAS 218156-96-8)

5.0(1)
Write a reviewAsk a question

See product citations (1)

Alternate Names:
SR protein phosphorylation inhibitor 340
Application:
SRPIN 340 is an SRPK1 inhibitor
CAS Number:
218156-96-8
Purity:
≥98%
Molecular Weight:
349.35
Molecular Formula:
C18H18F3N3O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

SRPIN 340 is a selective inhibitor of SRPK1 and SRPK2 (serine–arginine protein kinase), a protein kinase that phosphorylates proteins containing serine-arginine-rich domains. SRPIN 340 is competitive with ATP and does not inhibit other SRPKs significantly.SRPIN340, with a Ki value of 0.89 μM, serves as a specific inhibitor for Serine/arginine-rich protein kinase 1 (SRPK1). This kinase primarily targets proteins containing multiple serine/arginine (SR) dipeptides, such as the SR-rich splicing factor 1, known as SRSF1. SRPIN340 exhibits approximately 10-fold less potency against SRPK2 and shows no inhibitory effect on related kinases like Clk1 and Clk4.2.


SRPIN 340 (CAS 218156-96-8) References

  1. Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase.  |  Karakama, Y., et al. 2010. Antimicrob Agents Chemother. 54: 3179-86. PMID: 20498328
  2. Challenges to congenital genetic disorders with 'RNA-targeting' chemical compounds.  |  Ogawa, Y. and Hagiwara, M. 2012. Pharmacol Ther. 134: 298-305. PMID: 22342810
  3. Specific inhibition of serine/arginine-rich protein kinase attenuates choroidal neovascularization.  |  Dong, Z., et al. 2013. Mol Vis. 19: 536-43. PMID: 23559848
  4. SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity.  |  Gammons, MV., et al. 2013. Invest Ophthalmol Vis Sci. 54: 5797-806. PMID: 23761094
  5. Identification of a Dual Inhibitor of SRPK1 and CK2 That Attenuates Pathological Angiogenesis of Macular Degeneration in Mice.  |  Morooka, S., et al. 2015. Mol Pharmacol. 88: 316-25. PMID: 25993998
  6. Potential Antileukemia Effect and Structural Analyses of SRPK Inhibition by N-(2-(Piperidin-1-yl)-5-(Trifluoromethyl)Phenyl)Isonicotinamide (SRPIN340).  |  Siqueira, RP., et al. 2015. PLoS One. 10: e0134882. PMID: 26244849
  7. Trifluoromethyl arylamides with antileukemia effect and intracellular inhibitory activity over serine/arginine-rich protein kinases (SRPKs).  |  Siqueira, RP., et al. 2017. Eur J Med Chem. 134: 97-109. PMID: 28407594
  8. SRPIN340 protects heart muscle from oxidative damage via SRPK1/2 inhibition-mediated AKT activation.  |  Huang, J., et al. 2019. Biochem Biophys Res Commun. 510: 97-103. PMID: 30661787
  9. Nuclear Translocation of SRPKs Is Associated with 5-FU and Cisplatin Sensitivity in HeLa and T24 Cells.  |  Sigala, I., et al. 2021. Cells. 10: PMID: 33808326
  10. The SRPK inhibitor N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl) isonicotinamide (SRPIN340) increases the immune response against metastatic melanoma in mice.  |  Moreira, GA., et al. 2022. Biochem Pharmacol. 203: 115161. PMID: 35787994
  11. Immunomodulatory activity of trifluoromethyl arylamides derived from the SRPK inhibitor SRPIN340 and their potential use as vaccine adjuvant.  |  Mendes, FC., et al. 2022. Life Sci. 307: 120849. PMID: 35926588
  12. Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic-sensitizing effects on extranodal NK/T-cell lymphoma cells.  |  He, C., et al. 2022. BMC Cancer. 22: 1100. PMID: 36303126
  13. First evidence of a serine arginine protein kinase (SRPK) in leishmania braziliensis and its potential as therapeutic target.  |  Pimentel, DC., et al. 2023. Acta Trop. 238: 106801. PMID: 36563831

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

SRPIN 340, 10 mg

sc-394310
10 mg
$222.00